98%
921
2 minutes
20
Background: Because of the mutual influence of liver dysfunction and malignancy, overall survival (OS) is a composite clinical endpoint in hepatocellular carcinoma (HCC). We developed a nomogram integrating albumin-bilirubin (ALBI) grade, a new index of hepatic reserve, and tumor characteristics of HCC for predicting OS following curative liver resection.
Methods: The nomogram was built to estimate the probabilities of 1, 3, and 5-y OS based on training cohort of 709 HCC, which was validated in an international independent dataset. The prognostic value of the nomogram was determined by concordance index (C-index), time-dependent receiver operating characteristics (tdROC), and decision curves, comparing with ALBI grade alone, the Cancer of the Liver Italian Program (CLIP), the Barcelona Clinic Liver Cancer (BCLC), and Okuda staging systems.
Results: Independent factors derived from multivariable Cox analysis of the training cohort to predict OS were tumor grade, microvascular invasion, tumor size and ALBI grade which were assembled into nomogram. The calibration curves for probability of OS showed optimal agreement between nomogram-prediction and actual observation, which was tested in validation cohort. The C-index, tdROC and decision curves showed the nomogram was superior to CLIP, ALBI grade, BCLC and Okuda. The patients could also be stratified into low, intermediate risk, and high risk of the mortality by the normogram in both development and validation cohorts.
Conclusions: The nomogram integrating hepatic reserve and tumor characteristics provided a highly accurate estimation of OS in patients with HCC after curative liver resection, contributing to assess patient prognosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cca.2018.06.020 | DOI Listing |
Radiol Phys Technol
September 2025
Division of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa, Ishikawa, 920-0942, Japan.
This study evaluated whether temporal changes from the dynamic late phase to the hepatobiliary phase using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid supported liver tumor classification. A total of 147 patients with 165 lesions (hepatocellular carcinoma [HCC], metastases, and hemangiomas) underwent 3.0 T MRI.
View Article and Find Full Text PDFActa Med Philipp
July 2025
Division of Internal Medicine, National Kidney and Transplant Institute, Quezon City, Philippines.
Background And Objective: Patients with liver cirrhosis have an increased risk for poor postoperative outcomes after non-hepatic surgery, with liver dysfunction being the most important predictor of poor outcomes. This study aims to determine the association of the albumin-bilirubin (ALBI) grade, aspartate aminotransferase-platelet ratio index (APRI) score, and ALBI-APRI score with postoperative outcomes among cirrhotic patients who have undergone non-hepatic surgery.
Methods: This was a retrospective cohort study involving 34 patients.
In Vivo
August 2025
Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Türkiye.
Background/aim: Cholangiocarcinoma (CCA) is the second most frequently occurring primary malignant tumor of the liver, characterized by poor survival due to late diagnosis and limited treatment options. The albumin-bilirubin (ALBI) and platelet-ALBI (PALBI) scores, which reflect liver function and inflammation, have emerged as potential prognostic markers in hepatocellular carcinoma (HCC). Their prognostic significance in CCA, however, remains less established.
View Article and Find Full Text PDFCancer Med
September 2025
Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
Background/aim: The global aging population includes an increasing number of elderly patients with hepatocellular carcinoma (HCC). This study aimed to clarify the real-world outcomes, prognostic factors, and appropriate administration indicators for immunotherapy in elderly HCC patients.
Methods: This retrospective multicenter study analyzed 286 patients with unresectable HCC who received first-line immunotherapy (atezolizumab-bevacizumab or durvalumab-tremelimumab) between November 2020 and January 2024.
BMC Cancer
August 2025
Division of Gastroenterology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Background: The factors associated with extrahepatic recurrence (EHR) after curative resection for hepatocellular carcinoma (HCC) have rarely been investigated. This study examined the pre- and postoperative predictors of EHR after curative resection in HCC patients over a ten-year follow-up period.
Methods: A retrospective review was conducted on treatment-naïve HCC patients who underwent curative resection between 2004 and 2019 at four tertiary hospitals in South Korea.